News & Updates
Showing Multidisciplinary articles
Showing
High-dose semaglutide improves glucose metabolism outcomes in overweight/obese patients with T2D
Treatment with a higher dose of semaglutide led to significantly improved glucose metabolism outcomes in patients with overweight/obesity and type 2 diabetes (T2D) compared with a lower dose of semaglutide or placebo, according to the STEP* 2 trial presented at EASD 2021.
Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?
The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.
Atrophic gastritis, PPI use amplify EC risk in immunocompetent patients
In immunocompetent patients admitted at a community hospital, comorbidities such as advanced gastric cancer and atrophic gastritis (AG), as well as treatment with proton pump inhibitors (PPI), seem to aggravate the risk of developing oesophageal candidiasis (EC), a recent study has found.
Everolimus helps fight recurrent thymic neuroendocrine neoplasia
Treatment with everolimus appears to have beneficial effects on recurrent thymic neuroendocrine neoplasia (NEN), particularly well-differentiated tumours, with patients having a low Ki-67 index more likely to have a better outcome with the drug, as shown in a small study.
Therapeutic heparin may reduce death, bleeding risks in moderate COVID-19
Use of therapeutic heparin does not appear to significantly reduce the death, mechanical ventilation, or intensive care unit (ICU) admission in hospitalized patients with moderate COVID-19 and increased D-dimer levels, reveals a study. However, it is associated with a significantly lower chances of all-cause death and reduced risk of major bleeding.
